Projects
Next-generation immune biomarkers to improve clinical immunotherapy options for pediatric and adult patients with glioblastoma: a multi-omics, translational immunology and artificial intelligence-driven approach KU Leuven
The aim of this project is to present a clinically useful research protocol at the end of the 4 years that will use scientifically validated biomarkers to identify the most appropriate (combinations of) immunotherapies in a personalized way for every brain tumor patient, pediatric and adult. to select a clinical trial. To achieve this biomarker-based selection, combinations of the most advanced molecular cell biological research methods and ...
Training the next-generation of European GLIOblastoma (translational) researchers, to RESOLVE precision targeting of the brain tumour microenvironment. Flanders Institute for Biotechnology
Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics (GLIOTRAIN) - Marie Sklodowska-Curie actions (ITN) Flanders Institute for Biotechnology
Addition of WT1 mRNA-loaded autologous dendritic cell immunotherapy to adjuvant temozolomide chemotherapy after maximal, safe surgical resection and chemoradiation for newly diagnosed glioblastoma patients. University of Antwerp
Targeting radiation-induced plasticity in Glioblastoma: from fundamental insights to tailored therapeutic opportunities KU Leuven
Glioblastoma remains among the deadliest tumour-types without suitable cure. The failure of all clinical trials in the past decade can be attributed to the extensive (epi)genetic and phenotypic heterogeneity within and across patients, and the presence of ‘plastic’ cancer stem-like cells that can easily adapt to therapeutic interventions. Radiation therapy (RT), a cornerstone of the current standard-of-care, was previously shown to fuel GBM ...
Radiation-induced proneural-to-mesenchymal transition in glioblastoma: how does it work and how can it be prevented? KU Leuven
Glioblastomas (GBM) are malignant brain tumors that derive from progenitor cells or neuroglial stem cells. GBM are the most common primary brain tumors in adults and are treated with maximal surgical resection, radiotherapy and chemotherapy. However, the presence of chemo- and radioresistant cancer stem cells renders the treatment merely life-prolonging with a median 5-year survival of no more than 15 months. Investigating the molecular ...
Targeting radiation-induced plasticity in Glioblastoma: from fundamental insights to tailored therapeutic opportunities Ghent University
Glioblastoma (GBM) remains among the deadliest tumour-types without suitable cure. The failure of all clinical trials in the past decade can be attributed to the extensive (epi)genetic and phenotypic heterogeneity within and across patients, and the presence of ‘plastic’ cancer stem-like cells that can easily adapt to therapeutic interventions. Radiation therapy (RT), a cornerstone of the current standard-of-care, was previously shown to fuel ...